uniQure NV Company Profile (NASDAQ:QURE)

About uniQure NV

uniQure NV logouniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: QURE
  • CUSIP:
Key Metrics:
  • Previous Close: $8.19
  • 50 Day Moving Average: $8.19
  • 200 Day Moving Average: $10.18
  • 52-Week Range: $6.68 - $22.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.70
  • P/E Growth: 0.00
  • Market Cap: $205.30M
  • Outstanding Shares: 25,129,000
  • Beta: 0.17
Profitability:
  • Net Margins: -537.62%
  • Return on Equity: -61.96%
  • Return on Assets: -29.15%
Debt:
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 7.92%
  • Quick Ratio: 7.90%
Additional Links:
Companies Related to uniQure NV:

Analyst Ratings

Consensus Ratings for uniQure NV (NASDAQ:QURE) (?)
Ratings Breakdown: 10 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.11 (255.45% upside)

Analysts' Ratings History for uniQure NV (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetDetails
8/29/2016Leerink SwannReiterated RatingOutperform$27.00View Rating Details
8/19/2016Piper Jaffray Cos.Set Price TargetBuy$26.00 -> $16.00View Rating Details
8/4/2016HC WainwrightInitiated CoverageBuy$21.00View Rating Details
7/28/2016Jefferies GroupSet Price TargetBuy$28.00View Rating Details
7/28/2016Chardan CapitalSet Price TargetBuy$35.00View Rating Details
7/28/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/15/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$23.00View Rating Details
6/15/2016WallachBeth CapitalLower Price TargetBuy$60.00 -> $35.00View Rating Details
1/8/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details
1/8/2016Roth CapitalReiterated RatingBuy$37.00View Rating Details
5/9/2015BMO Capital MarketsReiterated RatingOutperform -> PositiveView Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for uniQure NV (NASDAQ:QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/28/2016        
8/25/2016Q2($0.89)($0.87)ViewN/AView Earnings Details
5/31/2016Q1($0.82)($0.93)ViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)ViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.14)ViewListenView Earnings Details
8/27/2015Q215($0.56)($0.98)ViewN/AView Earnings Details
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)ViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)ViewN/AView Earnings Details
6/6/2014($0.45)($0.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for uniQure NV (NASDAQ:QURE)
Current Year EPS Consensus Estimate: $-3.62 EPS
Next Year EPS Consensus Estimate: $-3.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)($0.63)($0.75)
Q2 20163($0.98)($0.74)($0.85)
Q3 20163($1.00)($0.77)($0.87)
Q4 20163($1.03)($0.80)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for uniQure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for uniQure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for uniQure NV (NASDAQ:QURE)
DateHeadline
globenewswire.com logouniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City - GlobeNewswire (press release) (NASDAQ:QURE)
globenewswire.com - September 28 at 12:09 PM
finance.yahoo.com logouniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City (NASDAQ:QURE)
finance.yahoo.com - September 26 at 11:47 AM
4-traders.com logouniQure : Announces Management and Board Changes (NASDAQ:QURE)
www.4-traders.com - September 22 at 6:41 PM
reuters.com logoBRIEF-Uniqure NV says Matthew Kapusta Appointed Interim CEO (NASDAQ:QURE)
www.reuters.com - September 22 at 6:41 PM
finance.yahoo.com logouniQure Announces Management and Board Changes (NASDAQ:QURE)
finance.yahoo.com - September 22 at 6:41 PM
News IconStock Perspective: uniQure N.V. (NASDAQ:QURE) Company Earnings Watch - Frisco Fastball (NASDAQ:QURE)
friscofastball.com - September 17 at 6:27 PM
News IconWhat are Research Firms Saying About uniQure N.V. (NASDAQ:QURE)? - Frisco Fastball (NASDAQ:QURE)
friscofastball.com - September 17 at 11:24 AM
4-traders.com logouniQure : Receives NASDAQ Deficiency Letter Related to Board Composition (NASDAQ:QURE)
www.4-traders.com - September 16 at 6:44 PM
News IconSell-side Consensus Sees uniQure N.V. (NASDAQ:QURE) Going Where Near-Term? - Frisco Fastball (NASDAQ:QURE)
friscofastball.com - September 16 at 10:31 AM
News IconAnalysts Take: uniQure N.V. (NASDAQ:QURE) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:QURE)
friscofastball.com - September 16 at 10:31 AM
globenewswire.com logouniQure Receives NASDAQ Deficiency Letter Related to Board Composition - GlobeNewswire (press release) (NASDAQ:QURE)
globenewswire.com - September 16 at 10:31 AM
finance.yahoo.com logouniQure Receives NASDAQ Deficiency Letter Related to Board Composition (NASDAQ:QURE)
finance.yahoo.com - September 16 at 10:31 AM
finance.yahoo.com logo7:16 am uniQure receives Nasdaq deficiency letter stating the co is not in compliance with the requirement that the majority of Board members be independent Directors (NASDAQ:QURE)
finance.yahoo.com - September 16 at 10:31 AM
reuters.com logoBRIEF-Uniqure Q2 loss per share eur 0.77 (NASDAQ:QURE)
www.reuters.com - August 25 at 7:11 PM
finance.yahoo.com logoUniQure reports 2Q loss (NASDAQ:QURE)
finance.yahoo.com - August 25 at 7:11 PM
finance.yahoo.com logouniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress (NASDAQ:QURE)
finance.yahoo.com - August 25 at 7:11 PM
News IconIs uniQure N.V. (NASDAQ:QURE) a Buy According to the Crowd? - Post News (NASDAQ:QURE)
www.kentuckypostnews.com - August 23 at 7:10 PM
News IconStock Moving Up in Session: uniQure N.V. (NASDAQ:QURE) - Post News (NASDAQ:QURE)
www.kentuckypostnews.com - August 22 at 6:56 PM
globenewswire.com logouniQure to Present at Upcoming Investor Conferences in September - GlobeNewswire (press release) (NASDAQ:QURE)
globenewswire.com - August 17 at 7:23 PM
finance.yahoo.com logouniQure to Present at Upcoming Investor Conferences in September (NASDAQ:QURE)
finance.yahoo.com - August 17 at 10:03 AM
News IconOne of the Best Biotech Stocks to Buy Could Return 52% in One Year (NASDAQ:QURE)
moneymorning.com - August 3 at 7:24 PM
thecountrycaller.com logoPfizer Inc. (PFE) to Explore Gene Therapy Portfolio (NASDAQ:QURE)
www.thecountrycaller.com - August 2 at 12:00 PM
nasdaq.com logoPfizer To Acquire Gene-Tech Company -- WSJ (NASDAQ:QURE)
www.nasdaq.com - August 2 at 12:00 PM
News IconPfizer acquires Bamboo Therapeutics (NASDAQ:QURE)
www.tradearabia.com - August 2 at 12:00 PM
News IconPfizer acquires Bamboo Therapeutics in $645 million deal (NASDAQ:QURE)
www.poandpo.com - August 1 at 6:49 PM
fortune.com logoPfizer Just Spent about $645 Million to Buy This Gene Therapy Company (NASDAQ:QURE)
fortune.com - August 1 at 6:49 PM
nasdaq.com logoPfizer to Buy Gene Therapy Company Bamboo Therapeutics (NASDAQ:QURE)
www.nasdaq.com - August 1 at 6:49 PM
marketwatch.com logoPfizer to buy gene therapy company Bamboo (NASDAQ:QURE)
www.marketwatch.com - August 1 at 11:43 AM
News IconPfizer acquires Bamboo Therapeutics to beef up gene therapy arsenal (NASDAQ:QURE)
www.channelnewsasia.com - August 1 at 11:43 AM
streetinsider.com logouniQure (QURE) Announces Updated Data from Ongoing Phase I/II trial of AMT-060 - StreetInsider.com (NASDAQ:QURE)
www.streetinsider.com - July 28 at 10:19 AM
reuters.com logoBRIEF-Uniqure presents updated clinical data in patients with severe Hemophilia B - Reuters (NASDAQ:QURE)
www.reuters.com - July 28 at 10:19 AM
publicnow.com logouniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect (NASDAQ:QURE)
www.publicnow.com - July 27 at 2:28 PM
ftsenews.co.uk logoNew Broker Ratings For Uniqure BV (NASDAQ:QURE) - FTSE News (NASDAQ:QURE)
www.ftsenews.co.uk - July 25 at 7:11 PM
News IconuniQure N.V. (NASDAQ:QURE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:QURE)
www.engelwooddaily.com - July 21 at 7:23 PM
News IconEPS Roundup: BJ's Restaurants, Inc. (NASDAQ:BJRI), uniQure N.V. (NASDAQ:QURE), Six Flags Entertainment ... - Engelwood Daily (NASDAQ:QURE)
www.engelwooddaily.com - July 20 at 7:54 PM
News IconEquity Roundup: Stock Performance Focus on uniQure N.V. (NASDAQ:QURE) - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 20 at 9:52 AM
News IconAs Gene Therapies Disrupt Big Pharma, Here's How to Get Your Piece of the Action (NASDAQ:QURE)
moneymorning.com - July 19 at 7:10 PM
News IconHow Many Uniqure NV (NASDAQ:QURE)'s Analysts Are Bearish? - Consumer Eagle (NASDAQ:QURE)
www.consumereagle.com - July 19 at 8:00 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for uniQure N.V. (NASDAQ:QURE) - TGP (NASDAQ:QURE)
telanaganapress.com - July 19 at 8:00 AM
fiscalstandard.com logoUniqure BV (NASDAQ:QURE) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:QURE)
www.fiscalstandard.com - July 17 at 6:27 PM
News IconUniqure NV Ord (NASDAQ:QURE) Shorted Shares Increased 4.23% After Market Selling - Consumer Eagle (NASDAQ:QURE)
www.consumereagle.com - July 17 at 6:27 PM
News IconUniqure NV Just Recorded A Sigfniciant Decline - Consumer Eagle (NASDAQ:QURE)
www.consumereagle.com - July 16 at 6:31 PM
investornewswire.com logoWill uniQure N.V. (NASDAQ:QURE) Surprise Analysts? - Investor Newswire (NASDAQ:QURE)
www.investornewswire.com - July 14 at 10:40 AM
News IconAnalyst Target and Average Rating Watch: uniQure N.V. (NASDAQ:QURE) - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 14 at 10:40 AM
finance.yahoo.com logouniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress (NASDAQ:QURE)
finance.yahoo.com - July 11 at 1:54 PM
reuters.com logoBRIEF-UniQure appoints Jonathan Garen as chief business officer - Reuters (NASDAQ:QURE)
www.reuters.com - July 9 at 6:25 PM
News IconUniqure NV Ord (NASDAQ:QURE) Sellers Increased By 4.23% Their Shorts - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 8 at 9:56 AM
news.cmlviz.com logouniQure NV Stock Momentum at Critical Inflection Point - CML News (NASDAQ:QURE)
news.cmlviz.com - July 8 at 9:56 AM
News IconCompany Stock Focus for uniQure N.V. (NASDAQ:QURE): Which Way Will Shares Head? - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 7 at 9:51 AM
smarteranalyst.com logoCompany Update (NASDAQ:QURE): Uniqure NV Appoints Jonathan Garen as Chief Business Officer - Smarter Analyst (NASDAQ:QURE)
www.smarteranalyst.com - July 7 at 9:51 AM

Social

uniQure NV (NASDAQ:QURE) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff